Metastatic Breast Cancer | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Metastatic Breast Cancer

Featuring perspectives from Dr Aditya Bardia, Dr Harold J Burstein, Prof Giuseppe Curigliano, Dr Sara A Hurvitz, Dr Hope S Rugo and Dr Joyce O’Shaughnessy, moderated by Dr Rugo, including the following topics: Introduction (0:00) Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Hurvitz (4:38) Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC — Dr Burstein (30:11) Selection and Sequencing of Treatment for Patients with HR-Positive, HER2-Negative mBC Who Experience Disease Progression on CDK4/6 Inhibition — Dr Rugo (48:15) Current and Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Prof Curigliano (1:07:24) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr O’Shaughnessy (1:22:11) Current and Future Strategies for the Care of Individuals with Endocrine-Refractory HR-Positive mBC — Dr Bardia (1:42:24) CME information and select publications